Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 15, 2020Expert Opinion on PharmacotherapyOpen Access

The limits and challenges of antiobesity pharmacotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

KGKishore M. GaddeKAKatelyn D. Atkins

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gadde et al. (2020) studied this question.

synapsesocial.com/papers/69d95ef55e5bcb4e3b835e2chttps://doi.org/10.1080/14656566.2020.1748599
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study2004 · 1,920 citations
  2. 2Obesity2018 · 633 citations
  3. 3Trends in cardiovascular disease risk factors by obesity level in adults in the United States, NHANES 1999‐20102014 · 184 citations
  4. 4A Population-Based Study of Appetite-Suppressant Drugs and the Risk of Cardiac-Valve Regurgitation1998 · 263 citations